Jubilant Pharmova's Spokane plant gets 8 FDA observations, none on sterility
No sterility concerns at key injectables unit, but 8 observations require a 15-day response. Spokane Line 3 expansion is the growth driver.
— 9 earlier stories on Jubilant Pharmova Ltd. →What's new
- USFDA completed inspection at Jubilant's Spokane facility and issued 8 Form 483 observations.
- None of the observations relate to sterility assurance, a critical area for sterile injectables.
- Company must respond within 15 business days; Spokane houses the accelerated Line 3 expansion.
Why this matters
For a mid-cap CDMO, a clean sterility report card at the Spokane site removes the most feared regulatory risk. Still, 8 observations demand remediation and come just weeks after a Warning Letter at the company's Montreal plant. The contrast shows Spokane is far cleaner than Montreal, keeping regulatory scrutiny in focus.
What we're watching
- Whether any observation triggers a more severe FDA action.
- Impact on Spokane Line 3 ramp-up and its $80-90M peak revenue projection.
- Any financial provisions or remediation costs disclosed.
The full read
The USFDA handed Jubilant Pharmova's Spokane facility 8 Form 483 observations after a completed inspection. None involve sterility assurance, the single biggest risk for a sterile injectables plant. That is the headline. Spokane is the company's key CDMO asset and home to the newly expanded Line 3, which management accelerated by two years and expects to generate $80-90M in peak revenue. Eight observations require a response within 15 business days and are not trivial, but they are a far cry from the Warning Letter the company's Montreal plant received just weeks ago. For a mid-cap with ₹15,505 cr market cap and ₹2,290 cr in quarterly sales, the Spokane inspection outcome removes the worst-case scenario. The open question is whether any of these observations widen into something more systemic.
Questions answered
- What does 'no sterility observations' mean for Jubilant's Spokane plant?
- It means the FDA found no issues with processes that ensure products are free from microorganisms. For a sterile injectables facility, this is the most important area; a sterility violation could halt production.
- How serious are 8 Form 483 observations?
- Eight is a moderate count. They require a written response within 15 business days. While not a Warning Letter, repeated or unresolved observations can escalate.
- How does this compare to the Montreal Warning Letter?
- Montreal received a Warning Letter, the FDA's most severe enforcement action short of seizure. Spokane's observations are less severe, but any regulatory action at a key site is notable.
- What is the Spokane Line 3 expansion?
- Line 3 is a newly expanded sterile injectables manufacturing line at the Spokane facility. Management accelerated its timeline, projecting peak revenue of $80-90M from it.
Jubilant Pharmova Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on JUBLPHARMA →- 19 Jun 2026 · 1:08 AM IST Jubilant Pharmova's Spokane plant gets 8 FDA observations, none on sterility
- 6d ago Jubilant Pharmova's ₹53.37 cr tax setback
- 12d ago Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
- 38d ago USFDA hits Jubilant's Montreal plant with a Warning Letter
- 45d ago Jubilant Pharmova subsidiary lands ₹107.89 cr tax demand